Eversept Partners LP Invests $10.68 Million in CytomX Therapeutics, Inc. $CTMX

Posted by Brenda Bartman on Jun 18th, 2026

Eversept Partners LP acquired a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,507,090 shares of the biotechnology company’s stock, valued at approximately $10,680,000.

Several other institutional investors also recently modified their holdings of CTMX. Orbimed Advisors LLC acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $19,208,000. Commodore Capital LP acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $17,462,000. Perceptive Advisors LLC acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $15,876,000. State Street Corp grew its holdings in shares of CytomX Therapeutics by 697.1% during the 4th quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock worth $21,900,000 after purchasing an additional 4,495,949 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $6,505,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock opened at $2.96 on Thursday. The company has a market capitalization of $503.76 million, a PE ratio of -7.22 and a beta of 2.08. CytomX Therapeutics, Inc. has a one year low of $1.72 and a one year high of $8.21. The business has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.46.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business had revenue of $10.26 million during the quarter, compared to the consensus estimate of $4.68 million. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%. Equities analysts anticipate that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Weiss Ratings lowered CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, March 19th. Jefferies Financial Group lifted their price objective on CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Oppenheimer reissued an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a report on Monday, March 16th. HC Wainwright decreased their price objective on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $7.00 to $12.00 in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CytomX Therapeutics has an average rating of “Moderate Buy” and an average target price of $12.10.

Check Out Our Latest Research Report on CTMX

CytomX Therapeutics Profile

(Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.